Bioleptin as a useful marker of metabolic status in children with diabetes mellitus type 1

Katarzyna Jakubek-Kipa1, Sabina Galiniak2, Katarzyna Łagowska3

  • 1Department of Pediatrics, Institute of Medical Sciences, Medical College of Rzeszów University, Rzeszów, Poland.

Frontiers in Endocrinology
|September 6, 2023
PubMed

Insights

Children with type 1 diabetes have lower leptin levels than healthy children. Biologically active leptin (bioLEP) levels varied significantly based on diabetes diagnosis, duration, and metabolic control.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Metabolic Disorders

Background:

  • Leptin plays a role in regulating metabolism.
  • Understanding leptin's role in type 1 diabetes is crucial for metabolic management.
  • Biologically active leptin (bioLEP) is a key indicator of leptin's function.

Purpose of the Study:

  • To measure serum leptin and bioLEP levels in children with type 1 diabetes.
  • To analyze these levels based on diabetes duration and metabolic control.
  • To compare levels between diabetic children and healthy controls.

Main Methods:

  • Study included 94 children with type 1 diabetes and 14 healthy controls.
  • Diabetic children were categorized into newly diagnosed and long-term groups (good/poor control).
  • Serum leptin and bioLEP were quantified using sandwich enzyme-linked immunosorbent assay.

Main Results:

  • Children with type 1 diabetes exhibited lower leptin levels than healthy children.
  • Newly diagnosed diabetic children had higher leptin than poorly controlled diabetic children.
  • Well-controlled diabetic children showed lower leptin levels than healthy children.

Conclusions:

  • Leptin and bioLEP levels differ significantly in children with type 1 diabetes based on disease status.
  • Further research on bioLEP in diabetes can elucidate metabolic regulation mechanisms.
  • Findings highlight the complex relationship between leptin, diabetes, and metabolic control in children.
Abstract

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
205
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
295
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
588
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
184